Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

Science Translational Medicine

Volumn 9, Issue 381, 2017, Pages

  Gholamin, Sharareh ^a,f   Mitra, Siddhartha S ^a   Feroze, Abdullah H ^a,g   Liu, Jie ^a,h   Kahn, Suzana A ^a   Zhang, Michael ^a   Esparza, Rogelio ^a   Richard, Chase ^a,i   Ramaswamy, Vijay ^b   Remke, Marc ^b,c   Volkmer, Anne K ^a,c   Willingham, Stephen ^a,j   Ponnuswami, Anitha ^a   McCarty, Aaron ^a   Lovelace, Patricia ^a   Storm, Theresa A ^a   Schubert, Simone ^a   Hutter, Gregor ^a,k   Narayanan, Cyndhavi ^a   Chu, Pauline ^a   Raabe, Eric H ^d   Harsh, Griffith ^a   Taylor, Michael D ^b   Monje, Michelle ^a   Cho, Yoon Jae ^e   Majeti, Ravi ^a   Volkmer, Jens P ^a,h   Fisher, Paul G ^a   Grant, Gerald ^a   Steinberg, Gary K ^a   Vogel, Hannes ^a   Edwards, Michael ^a   Weissman, Irving L ^a   Cheshier, Samuel H ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f California Institute of Technology   (United States)

^g UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^h Forty Seven Inc   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j University of Pennsylvania ^*  (United States)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU5F9 G4; UNCLASSIFIED DRUG; ANTIBODY; CD47 PROTEIN, HUMAN; DIFFERENTIATION ANTIGEN; IMMUNOGLOBULIN RECEPTOR; SIRPA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; BRAIN TUMOR; CANCER INHIBITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MENINGEAL METASTASIS; METASTASIS INHIBITION; MOUSE; NEURAL STEM CELL; NEUROECTODERM TUMOR; NONHUMAN; PHAGOCYTOSIS; PONTINE GLIOMA; SURVIVAL RATE; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL PROLIFERATION; CHILD; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; IMMUNOCOMPETENCE; IMMUNOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MENINGIOMA; METABOLISM; METASTASIS; PATHOLOGY; SECONDARY; SURVIVAL ANALYSIS;

ANIMALS; ANTIBODIES; ANTIGENS, DIFFERENTIATION; BRAIN NEOPLASMS; CD47 ANTIGEN; CELL PROLIFERATION; CHILD; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCOMPETENCE; INJECTIONS, INTRAVENTRICULAR; MEDULLOBLASTOMA; MENINGEAL NEOPLASMS; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHAGOCYTOSIS; RECEPTORS, IMMUNOLOGIC; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016424015     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf2968     Document Type: Article

References (57)

1. I. F. Pollack, R. I. Jakacki, Childhood brain tumors: Epidemiology, current management and future directions. Nat. Rev. Neurol. 7, 495-506 (2011).
2. I. F. Pollack, Multidisciplinary management of childhood brain tumors: A review of outcomes, recent advances, and challenges. J. Neurosurg. Pediatr. 8, 135-148 (2011).
3. B. L. Maria, K. Rehder, T. A. Eskin, L. M. Hamed, E. B. Fennell, R. G. Quisling, J. P. Mickle, R. B. Marcus, W. E. Drane, N. P. Mendenhall, W. M. McCollough, A. Kedar, Brainstem glioma: I. Pathology, clinical features, and therapy. J. Child Neurol. 8, 112-128 (1993).
4. P. A. Northcott, A. Korshunov, H. Witt, T. Hielscher, C. G. Eberhart, S. Mack, E. Bouffet, S. C. Clifford, C. E. Hawkins, P. French, J. T. Rutka, S. Pfister, M. D. Taylor, Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 29, 1408-1414 (2011).
5. S. M. Castellino, N. J. Ullrich, M. J. Whelen, B. J. Lange, Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J. Natl. Cancer Inst. 106, dju186 (2014).
6. C. M. Suryadevara, T. Verla, L. Sanchez-Perez, E. A. Reap, B. D. Choi, P. E. Fecci, J. H. Sampson, Immunotherapy for malignant glioma. Surg. Neurol. Int. 6, S68-S77 (2015).
7. E. J. Brown, W. A. Frazier, Integrin-Associated protein (CD47) and its ligands. Trends Cell Biol. 11, 130-135 (2001).
8. S. Jaiswal, C. H. M. Jamieson, W. W. Pang, C. Y. Park, M. P. Chao, R. Majeti, D. Traver, N. van Rooijen, I. L. Weissman, CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
9. D. Traver, K. Akashi, I. L. Weissman, E. Lagasse, Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9, 47-57 (1998).
10. S. Jaiswal, D. Traver, T. Miyamoto, K. Akashi, E. Lagasse, I. L. Weissman, Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc. Natl. Acad. Sci. U.S.A. 100, 10002-10007 (2003).
11. R. Majeti, M. P. Chao, A. A. Alizadeh, W. W. Pang, S. Jaiswal, K. D. Gibbs Jr., N. van Rooijen, I. L. Weissman, CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
12. M. P. Chao, A. A. Alizadeh, C. Tang, M. Jan, R. Weissman-Tsukamoto, F. Zhao, C. Y. Park, I. L. Weissman, R. Majeti, Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374-1384 (2011).
13. S. B. Willingham, J.-P. Volkmer, A. J. Gentles, D. Sahoo, P. Dalerba, S. S. Mitra, J. Wang, H. Contreras-Trujillo, R. Martin, J. D. Cohen, P. Lovelace, F. A. Scheeren, M. P. Chao, K. Weiskopf, C. Tang, A. K. Volkmer, T. J. Naik, T. A. Storm, A. R. Mosley, B. Edris, S. M. Schmid, C. K. Sun, M.-S. Chua, O. Murillo, P. Rajendran, A. C. Cha, R. K. Chin, D. Kim, M. Adorno, T. Raveh, D. Tseng, S. Jaiswal, P. O. Enger, G. K. Steinberg, G. Li, S. K. So, R. Majeti, G. R. Harsh, M. van de Rijn, N. N. H. Teng, J. B. Sunwoo, A. A. Alizadeh, M. F. Clarke, I. L. Weissman, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 109, 6662-6667 (2012).
14. B. Edris, K. Weiskopf, A. K. Volkmer, J.-P. Volkmer, S. B. Willingham, H. Contreras-Trujillo, J. Liu, R. Majeti, R. B. West, J. A. Fletcher, A. H. Beck, I. L. Weissman, M. van de Rijn, Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. U.S.A. 109, 6656-6661 (2012).
15. D. Kim, J. Wang, S. B. Willingham, R. Martin, G. Wernig, I. L. Weissman, Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26, 2538-2545 (2012).
16. A. N. Barclay, T. K. van den Berg, The interaction between signal regulatory protein alpha (SIRPa) and CD47: Structure, function, and therapeutic target. Annu. Rev. Immunol. 32, 25-50 (2014).
17. S. J. Gardai, K. A. McPhillips, S. C. Frasch, W. J. Janssen, A. Starefeldt, J. E. Murphy-Ullrich, D. L. Bratton, P.-A. Oldenborg, M. Michalak, P. M. Henson, Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-Activation of LRP on the phagocyte. Cell 123, 321-334 (2005).
18. S. J. Gardai, D. L. Bratton, C. A. Ogden, P. M. Henson, Recognition ligands on apoptotic cells: A perspective. J. Leukoc. Biol. 79, 896-903 (2006).
19. M. P. Chao, I. L. Weissman, R. Majeti, The CD47-SIRPa pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225-232 (2012).
20. M. P. Chao, S. Jaiswal, R. Weissman-Tsukamoto, A. A. Alizadeh, A. J. Gentles, J. Volkmer, K. Weiskopf, S. B. Willingham, T. Raveh, C. Y. Park, R. Majeti, I. L. Weissman, Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63ra94 (2010).
21. M. P. Chao, C. Tang, R. K. Pachynski, R. Chin, R. Majeti, I. L. Weissman, Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118, 4890-4901 (2011).
22. J. Liu, L. Wang, F. Zhao, S. Tseng, C. Narayanan, L. Shura, S. Willingham, M. Howard, S. Prohaska, J. Volkmer, M. Chao, I. L. Weissman, R. Majeti, Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLOS ONE 10, e0137345 (2015).
23. M. Kool, A. Korshunov, M. Remke, D. T. W. Jones, M. Schlanstein, P. A. Northcott, Y.-J. Cho, J. Koster, A. Schouten-van Meeteren, D. van Vuurden, S. C. Clifford, T. Pietsch, A. O. von Bueren, S. Rutkowski, M. McCabe, V. P. Collins, M. L. Bäcklund, C. Haberler, F. Bourdeaut, O. Delattre, F. Doz, D. W. Ellison, R. J. Gilbertson, S. L. Pomeroy, M. D. Taylor, P. Lichter, S. M. Pfister, Molecular subgroups of medulloblastoma: An international meta-Analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 123, 473-484 (2012).
24. T.-A. Read, M. P. Fogarty, S. L. Markant, R. E. McLendon, Z. Wei, D. W. Ellison, P. G. Febbo, R. J. Wechsler-Reya, Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 15, 135-147 (2009).
25. R. J. Ward, L. Lee, K. Graham, T. Satkunendran, K. Yoshikawa, E. Ling, L. Harper, R. Austin, E. Nieuwenhuis, I. D. Clarke, C.-c. Hui, P. B. Dirks, Multipotent CD15+ cancer stem cells in Patched-1-deficient mouse medulloblastoma. Cancer Res. 69, 4682-4690 (2009).
26. P. A. Northcott, A. Korshunov, S. M. Pfister, M. D. Taylor, The clinical implications of medulloblastoma subgroups. Nat. Rev. Neurol. 8, 340-351 (2012).
27. M. Monje, P. G. Fisher, Neurological complications following treatment of children with brain tumors. J. Pediatr. Rehabil. Med. 4, 31-36 (2011).
28. N. Uchida, D. W. Buck, D. He, M. J. Reitsma, M. Masek, T. V. Phan, A. S. Tsukamoto, F. H. Gage, I. L. Weissman, Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. U.S.A. 97, 14720-14725 (2000).
29. S. Tamaki, K. Eckert, D. He, R. Sutton, M. Doshe, G. Jain, R. Tushinski, M. Reitsma, B. Harris, A. Tsukamoto, F. Gage, I. Weissman, N. Uchida, Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J. Neurosci. Res. 69, 976-986 (2002).
30. K. J. Cohen, R. L. Heideman, T. Zhou, E. J. Holmes, R. S. Lavey, E. Bouffet, I. F. Pollack, Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children's Oncology Group. Neuro Oncol. 13, 410-416 (2011).
31. A. M. Donson, D. K. Birks, V. N. Barton, Q. Wei, B. K. Kleinschmidt-Demasters, M. H. Handler, A. E. Waziri, M. Wang, N. K. Foreman, Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J. Immunol. 183, 7428-7440 (2009).
32. L. M. Hoffman, A. M. Donson, I. Nakachi, A. M. Griesinger, D. K. Birks, V. Amani, M. S. Hemenway, A. K. Liu, M. Wang, T. C. Hankinson, M. H. Handler, N. K. Foreman, Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol. 127, 731-745 (2014).
33. K. Wani, T. S. Armstrong, E. Vera-Bolanos, A. Raghunathan, D. Ellison, R. Gilbertson, B. Vaillant, S. Goldman, R. J. Packer, M. Fouladi, I. Pollack, T. Mikkelsen, M. Prados, A. Omuro, R. Soffietti, A. Ledoux, C. Wilson, L. Long, M. R. Gilbert, K. Aldape; Collaborative Ependymoma Research Network, A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 123, 727-738 (2012).
34. S. Miller, H. A. Rogers, P. Lyon, V. Rand, M. Adamowicz-Brice, S. C. Clifford, J. T. Hayden, S. Dyer, S. Pfister, A. Korshunov, M.-A. Brundler, J. Lowe, B. Coyle, R. G. Grundy, Genomewide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol. 13, 866-879 (2011).
35. J. A. Knipstein, D. K. Birks, A. M. Donson, I. Alimova, N. K. Foreman, R. Vibhakar, Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol. 14, 175-183 (2012).
36. R. B. Roth, P. Hevezi, J. Lee, D. Willhite, S. M. Lechner, A. C. Foster, A. Zlotnik, Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 7, 67-80 (2006).
37. Y.-J. Cho, A. Tsherniak, P. Tamayo, S. Santagata, A. Ligon, H. Greulich, R. Berhoukim, V. Amani, L. Goumnerova, C. G. Eberhart, C. C. Lau, J. M. Olson, R. J. Gilbertson, A. Gajjar, O. Delattre, M. Kool, K. Ligon, M. Meyerson, J. P. Mesirov, S. L. Pomeroy, Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 29, 1424-1430 (2011).
38. M. Monje, S. S. Mitra, M. E. Freret, T. B. Raveh, J. Kim, M. Masek, J. L. Attema, G. Li, T. Haddix, M. S. B. Edwards, P. G. Fisher, I. L. Weissman, D. H. Rowitch, H. Vogel, A. J. Wong, P. A. Beachy, Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc. Natl. Acad. Sci. U.S.A. 108, 4453-4458 (2011).
39. K. L. Ligon, E. Huillard, S. Mehta, S. Kesari, H. Liu, J. A. Alberta, R. M. Bachoo, M. Kane, D. N. Louis, R. A. Depinho, D. J. Anderson, C. D. Stiles, D. H. Rowitch, Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53, 503-517 (2007).
40. K. L. Ligon, J. A. Alberta, A. T. Kho, J. Weiss, M. R. Kwaan, C. L. Nutt, D. N. Louis, C. D. Stiles, D. H. Rowitch, The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J. Neuropathol. Exp. Neurol. 63, 499-509 (2004).
41. J. I. Ausman, W. R. Shapiro, D. P. Rall, Studies on the chemotherapy of experimental brain tumors: Development of an experimental model. Cancer Res. 30, 2394-2400 (1970).
42. R. K. Mulhern, S. L. Palmer, Neurocognitive late effects in pediatric cancer. Curr. Probl. Cancer 27, 177-197 (2003).
43. J. S. Tsuruda, K. E. Kortman, W. G. Bradley, D. C. Wheeler, W. Van Dalsem, T. P. Bradley, Radiation effects on cerebral white matter: MR evaluation. AJR Am. J. Roentgenol. 149, 165-171 (1987).
44. T. A. Glauser, R. J. Packer, Cognitive deficits in long-term survivors of childhood brain tumors. Childs Nerv. Syst. 7, 2-12 (1991).
45. V. Ramaswamy, M. Remke, E. Bouffet, C. C. Faria, S. Perreault, Y.-J. Cho, D. J. Shih, B. Luu, A. M. Dubuc, P. A. Northcott, U. Schüller, S. Gururangan, R. McLendon, D. Bigner, M. Fouladi, K. L. Ligon, S. L. Pomeroy, S. Dunn, J. Triscott, N. Jabado, A. Fontebasso, D. T. W. Jones, M. Kool, M. A. Karajannis, S. L. Gardner, D. Zagzag, S. Nunes, J. Pimentel, J. Mora, E. Lipp, A. W. Walter, M. Ryzhova, O. Zheludkova, E. Kumirova, J. Alshami, S. E. Croul, J. T. Rutka, C. Hawkins, U. Tabori, K.-E. T. Codispoti, R. J. Packer, S. M. Pfister, A. Korshunov, M. D. Taylor, Recurrence patterns across medulloblastoma subgroups: An integrated clinical and molecular analysis. Lancet Oncol. 14, 1200-1207 (2013).
46. S. Shukla, S. M. Meeran, Epigenetics of cancer stem cells: Pathways and therapeutics. Biochim. Biophys. Acta 1840, 3494-3502 (2014).
47. J. D. O'Flaherty, M. Barr, D. Fennell, D. Richard, J. Reynolds, J. O'Leary, K. O'Byrne, The cancer stem-cell hypothesis: Its emerging role in lung cancer biology and its relevance for future therapy. J. Thorac. Oncol. 7, 1880-1890 (2012).
48. M. J. Carson, J. M. Doose, B. Melchior, C. D. Schmid, C. C. Ploix, CNS immune privilege: Hiding in plain sight. Immunol. Rev. 213, 48-65 (2006).
49. D. C. Davies, Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J. Anat. 200, 639-646 (2002).
50. R. S. Klein, L. Izikson, T. Means, H. D. Gibson, E. Lin, R. A. Sobel, H. L. Weiner, A. D. Luster, IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J. Immunol. 172, 550-559 (2004).
51. L. A. Lampson, Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs 3, 153-160 (2011).
52. D. Tseng, J.-P. Volkmer, S. B. Willingham, H. Contreras-Trujillo, J. W. Fathman, N. B. Fernhoff, J. Seita, M. A. Inlay, K. Weiskopf, M. Miyanishi, I. L. Weissman, Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl. Acad. Sci. U.S.A. 110, 11103-11108 (2013).
53. X. Liu, Y. Pu, K. Cron, L. Deng, J. Kline, W. A. Frazier, H. Xu, H. Peng, Y.-X. Fu, M. M. Xu, CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209-1215 (2015).
54. R. A. Beckman, L. M. Weiner, H. M. Davis, Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179 (2007).
55. K. Weiskopf, A. M. Ring, C. C. M. Ho, J.-P. Volkmer, A. M. Levin, A. K. Volkmer, E. Özkan, N. B. Fernhoff, M. van de Rijn, I. L. Weissman, K. C. Garcia, Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88-91 (2013).
56. P. Bandopadhayay, G. Bergthold, B. Nguyen, S. Schubert, S Gholamin, Y. Tang, S. Bolin, S. E. Schumacher, R. Zeid, S. Masoud, F. Yu, N. Vue, W. J. Gibson, B. R. Paolella, S. S. Mitra, S. H. Cheshier, J. Qi, K.-W. Liu, R. Wechsler-Reya, W. A. Weiss, F. J. Swartling, M. W. Kieran, J. E. Bradner, R. Beroukhim, Y.-J. Cho, BET bromodomain inhibition of MYC-Amplified medulloblastoma. Clin. Cancer Res. 20, 912-925 (2014).
57. S. Gholamin, S. S. Mitra, A. H. Feroze, J. Liu, S. A. Kahn, M. Zhang, R. Esparza, C. Richard, V. Ramaswamy, M. Remke, A. K. Volkmer, S. Willingham, A. Ponnuswami, A. McCarty, P. Lovelace, T. A. Storm, S. Schubert, G. Hutter, C. Narayanan, P. Chu, E. H. Raabe, G. Harsh, M. D. Taylor, M. Monje, Y.-J. Cho, R. Majeti, J. P. Volkmer, P. G. Fisher, G. Grant, G. K. Steinberg, H. Vogel, M. Edwards, I. L. Weissman, S. H. Cheshier, Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med. 9, eaaf2968 (2017).